Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
Active as of 2022-01-10 |
Generated Narrative: Citation 58
version: 25; Last updated: 2024-11-16 19:17:38+0000
identifier: FEvIR Object Identifier/https://fevir.net/FOI/58, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.20
version: 2.0.0-ballot
title: Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
status: Active
date: 2022-01-10 13:29:15+0000
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description:
This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
Code | Value[x] |
Citation Classification Type fevir-platform-use: FEvIR Platform Use | FHIR Resource |
jurisdiction: World
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
author: Brian S. Alper:
Style | Text |
Computable Publishing | 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) [FHIR Resource], version 4. Contributors: Brian S. Alper, Joanne Dehnbostel, Khalid Shahin [Authors]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 55. Created December 17, 2020. Revised December 21, 2020. Accessed March 13, 2021. Available at: https://fevir.net/resources/Evidence/55. Computable resource at: https://fevir.net/resources/Evidence/55. |
Type | ResourceReference |
Derived From | 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) |
citedArtifact
identifier: FEvIR Object Identifier/55
dateAccessed: 2021-03-13
Versions
Value 4 StatusDates
Activity Actual Period Created true ?? --> 2020-12-17 Titles
Type Language Text Primary title English 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY).
Abstracts
Type Language Text Copyright Primary human use English COVID-19 pneumonia remdesivir vs. placebo 14-day mortality (779 events among 6,744 participants, 3 randomized trials)\nRisk ratio 0.85 (95% CI 0.74 to 0.96) in fixed-effect analysis\nRisk ratio 0.81 (95% CI 0.60 to 1.08) in random-effects analysis
https://creativecommons.org/licenses/by-nc-sa/4.0/
publicationForm
PublishedIns
Type Title Publisher PublisherLocation Database Fast Evidence Interoperability Resources (FEvIR) Platform Computable Publishing LLC Ipswich, MA, USA lastRevisionDate: 2020-12-21
language: English
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
webLocation
classifier: JSON, Computable resource
classification
type: Knowledge Artifact Type
classifier: FHIR Resource
classification
type: fhir-resource
classifier: Evidence
classification
type: defined-in-text
classifier: remdesivir, COVID-19, pharmaceutical treatment
contributorship
complete: true
entry
contributor: Practitioner Brian S. Alper
forenameInitials: BS
affiliation: Computable Publishing LLC
contributionType: Conceptualization, Data curation, Supervision
role: Author/Creator
correspondingContact: true
entry
contributor: Practitioner Joanne Dehnbostel
forenameInitials: J
affiliation: Computable Publishing LLC
contributionType: Formal analysis, Data curation
role: Author/Creator
correspondingContact: false
entry
contributor: Practitioner Khalid Shahin
forenameInitials: K
affiliation: Computable Publishing LLC
contributionType: Software
role: Author/Creator
correspondingContact: false
Generated Narrative: Practitioner #contributor0
identifier:
https://orcid.org/
/0000-0003-4300-4928name: Brian S. Alper
telecom: balper@computablepublishing.com
Generated Narrative: Practitioner #contributor1
name: Joanne Dehnbostel
telecom: jdehnbostel@computablepublishing.com
Generated Narrative: Practitioner #contributor2
name: Khalid Shahin
telecom: kshahin@computablepublishing.com